Beta-Nicotinamide Mononucleotide Crystals Enzymatic Reactivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

β-Nicotinamide mononucleotide (β-NMN) products with high purities as measured by HPLC do not produce consistent physiological effects when administered, indicating differences in enzymatic reactivity despite comparable purities, necessitating a compound with high purity and enzymatic reactivity for enhanced physiological activity.

Innovation Solution

A compound comprising β-nicotinamide mononucleotide or its pharmacologically acceptable salt with a purity of 95% or higher and enzymatic reactivity of 30 units or higher with lactate dehydrogenase, preferably in crystalline form, derived from mammalian skeletal muscle, and substantially free from nicotinamide dinucleotide, along with methods for evaluating and determining the compound's quality and reactivity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If β-NMN products are purified to high purity levels as measured by HPLC, then purity is improved, but enzymatic reactivity remains inconsistent and physiological activity does not improve

Engineering Contradiction:

ImprovepurityVSAvoidenzymatic reactivity

Core Design Contradiction:

Manufacturing precisionVSReliability

Solution Approach 1:

The patent changes the measurement parameter from HPLC purity to enzymatic reactivity (activity units) to evaluate β-NMN quality. This parameter change reveals that HPLC purity does not correlate with physiological activity, leading to the establishment of new quality standards based on enzymatic activity measurements rather than just chromatographic purity.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the mechanical/chemical analysis method (HPLC) with a biological assay method (enzymatic reactivity measurement using lactate dehydrogenase). This substitution allows direct measurement of the functional property (enzymatic activity) that correlates with physiological effect, rather than relying on indirect purity measurements.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Manufacturing precision

If β-NMN is crystallized to increase purity, then purity is improved, but physiological activity remains inconsistent

Engineering Contradiction:

ImprovepurityVSAvoidphysiological activity

Core Design Contradiction:

Manufacturing precisionVSProductivity

Solution Approach 1:

The patent establishes new quality parameters that include both purity and enzymatic reactivity (activity units ≥30). This dual-parameter approach ensures that crystallized products are evaluated not only for purity but also for functional activity, preventing the release of crystallized material that may have high purity but low physiological effectiveness.

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If HPLC purity measurement is used as the sole quality criterion, then measurement simplicity is improved, but physiological activity evaluation is insufficient

Engineering Contradiction:

Improvemeasurement simplicityVSAvoidphysiological activity assessment

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent introduces lactate dehydrogenase as an intermediary substance to measure enzymatic reactivity. This enzyme acts as a mediator that converts the chemical property of β-NMN into a measurable signal (NADH production detected by absorbance change), providing a quantitative assessment of physiological activity that complements HPLC purity measurement.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compound achieves high physiological activity and bioavailability by ensuring high purity and enzymatic reactivity, surpassing the limitations of traditional β-NMN products, thereby providing effective pharmaceutical, dietary, and cosmetic applications.

Implementation Method 1

a reactivity of the compound with lactate dehydrogenase is 30 units or higher

Methodology Applied

Scientific EffectEnzymatic reaction: Enzyme

Data Source

PatentUS20230348520A1Compound comprising beta-nicotinamide mononucleotide or pharmacologically acceptable salt thereof, and method for evaluating quality and method for assessing enzymatic reactivity of said compound

Publication Date: 2023.11.02 ORIENTAL YEAST

AI summary

A compound includes β-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof. A purity of the compound as measured through HPLC is 95% or higher. A reactivity of the compound with lactate dehydrogenase is 30 units or higher.